Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...

Patients can now easily buy these tests, but cardiologists must consider their quality when using the information to guide ...

Analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today ...

单基因糖尿病（Monogenic diabetes）是由单个基因或染色体位点的一个或多个缺陷引起。该疾病可能在家族内作为显性、隐性或非孟德尔性状遗传，但也可能由于新发突变而自发出现。

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

ElevateBio has entered into a multiyear collaboration with Amazon's cloud arm to identify treatment targets and new CRISPR systems.

The company’s technology also benefitted from $401m in Series D financing in June 2023. ElevateBio’s CEO David Hallal said: ...

DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus ...